What are the key drivers for the 6% year-over-year increase in revenue per visit (TRPV)? Is it acuity, contracting, or something else?

The primary driver is payer contracting, with good line of sight into rate increases for the full year. Management has constructive dialogue with payers to ensure access to high-quality mental health care. “From an overall kind of payer perspective, we continue to have good constructive dialogue with them in terms of making sure that they're providing the access to high-quality mental health care that we offer.”

What are the long-term EBITDA margin goals, given the strong 15.2% in Q2 and 13.2% for the full year?

Management reaffirmed long-term margins in the 15% to 20% range, with 20% not being a ceiling. They also reiterated mid-teen margins by FY28, but are not refining long-term targets at this point. “So we've gone out there saying long-term margins in the 15% to 20% range with 20% not being a ceiling on it. We actually further dimension that in our Q4 call just around the 2028 margins and having mid-teen margins by full year 2028.”

What are the gating factors for the rollout of specialty services like TMS and Spravato, and what are the plans and hurdles?

Specialty services (neuropsych testing, TMS, Spravato) are a tremendous opportunity, expected to grow 40% this year. Gating factors are primarily internal, refining the operating model and nuances across states/payers. They expect to accelerate rollout in coming years. “And I would view the gating is more us than anything else in the macro environment. And then we would expect to be accelerating rollout in coming years.”

LFST

LifeStance (LFST) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

LifeStance Q2 FY26 — Exceeds Guidance with Strong Revenue Growth and Margin Expansion

LifeStance Health delivered another strong quarter, surpassing guidance with robust revenue growth and significant adjusted EBITDA margin expansion, driven by increased clinician productivity and effective payer contracting. The company is strategically investing in technology, specialty services, and geographic expansion via tuck-in acquisitions, while preparing for a new EHR rollout in 2027. Management emphasizes its commitment to clinical outcomes and maintaining constructive payer relationships, positioning for sustained long-term growth despite near-term investment impacts.

Highlights

Revenue grew over 26% to $435 million, exceeding expectations.
Adjusted EBITDA increased 94% to $66 million, with margins exceeding 15.2%.
Clinician base grew to over 8,500, an 11% increase, with strong productivity (visits per average clinician up 7% YoY).
Free cash flow generated $88 million, up from $57 million in the prior year.
Full-year guidance raised across all metrics, with revenue midpoint up $45 million and Adjusted EBITDA midpoint up $15 million.

Concerns

Investments in patient acquisition, technology, clinical excellence, and clinician compensation will impact Q3 EBITDA, which is expected to be down sequentially to $49 million to $59 million.
The transition to a new EHR planned for 2027 is expected to cause a "short-term blip in productivity" for clinicians.

Guidance & targets

Category	Target	Timeline	Confidence
Full Year 2026 Revenue	$1.685 billion to $1.725 billion high materiality	FY26	High
Full Year 2026 Center Margin	$570 million to $594 million medium materiality	FY26	High
Full Year 2026 Adjusted EBITDA	$215 million to $235 million high materiality	FY26	High
Full Year 2026 Stock-Based Compensation	approximately $60 million to $70 million low materiality	FY26	Medium
Q3 2026 Revenue	$420 million to $440 million medium materiality	Q3 · FY26	High
Q3 2026 Center Margin	$140 million to $152 million medium materiality	Q3 · FY26	High
Q3 2026 Adjusted EBITDA	$49 million to $59 million medium materiality	Q3 · FY26	High
Long-term Adjusted EBITDA Margin	15% to 20% range high materiality	Long-term	High
FY28 Adjusted EBITDA Margin	mid-teen margins high materiality	FY28	High
Long-term Visit Growth	low double-digit visit growth year-over-year medium materiality	Long-term	High

LFST operating KPIs by quarter

LFST operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Dec 2025 Q4 FY25	This call Jun 2026 Q2 FY26	Change vs prior quarter
Employees Clinicians	8,040 We grew our net clinicians by 44 in the fourth quarter and 657 for the full year, bringing our total clinician base to 8,040, representing growth of 9% year-over-year. Source: earnings call transcript	8,542 This was achieved while at the same time adding 193 clinicians in the second quarter, bringing our total clinician base to 8,542, representing growth of 11%. Source: earnings call transcript	+6.2%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Deals & partnerships

Undisclosed Small tuck-in acquisition

Expands therapy and psychiatry presence in Arizona. Primary intent for M&A is to open up new geographies.

Risks & headwinds

Short-term blip in clinician productivity during new EHR rollout Next year (2027)

Not quantified, but acknowledged as an impact.

Mitigation:Working to minimize disruption as much as possible.

Adjusted EBITDA expected to decline sequentially in Q3 FY26 Q3 FY26

Q3 Adjusted EBITDA guidance of $49 million to $59 million, down from Q2's $66 million.

Mitigation:Due to planned strategic investments in patient acquisition, technology, clinical excellence, and clinician compensation to support long-term growth.

Impact of payroll and 401(k) match payments on Q3 FCF Q3 FY26

Roughly $60 million

Mitigation:Benefited from favorable timing in Q2, now impacting Q3.

What to watch in Q3 FY26

Q3 FY26 Adjusted EBITDA Performance

Q3 FY26

Current $66 million (Q2 FY26)

Target Within $49 million to $59 million range

Why it matters

To confirm management's ability to balance strategic investments with profitability and meet sequential guidance.

For the third quarter, we expect revenue of $420 million to $440 million, Center Margin of $140 million to $152 million and adjusted EBITDA of $49 million to $59 million.

Find out whether LFST delivers this. Inve re-checks your case every morning.

Q&A highlights

What levers remain to pull on clinician productivity given difficult comps?

Management stated it's their fourth quarter of strong productivity and they continue to evaluate opportunities. Levers include improving new patient conversion, optimizing clinician schedules, and balancing existing capacity utilization with new clinician adds. They currently utilize about 70% of clinician time.

“We're utilizing right now about 70% of the time that clinicians give us.”

asked by Craig Hettenbach · answered by David Bourdon

2 min read 7 chapters

Detailed narrative

Strong Q2 Outperformance and Raised Full-Year Outlook

LifeStance exceeded all guided metrics for Q2 FY26, delivering over 26% revenue growth to $435 million and adjusted EBITDA margins exceeding 15.2%. This strong performance led to a full-year guidance raise across all metrics, with the revenue midpoint increasing by $45 million and adjusted EBITDA midpoint by $15 million, reflecting confidence in continued momentum.

Clinician Growth and Productivity

The company's clinician base expanded to over 8,500, representing 11% year-over-year growth, driven by a compelling value proposition that resonates across various clinician cohorts. Clinician productivity remained strong for the fourth consecutive quarter, with visits per average clinician increasing 7% year-over-year, contributing significantly to visit volume growth of 19%.

Strategic Investments for Future Growth

Management plans to make additional investments in the second half of FY26, including patient acquisition and marketing, technology and AI enablement, clinical excellence teams, and enhanced clinician compensation. These investments are reflected in the updated outlook and are aimed at supporting long-term growth objectives, even if they lead to a sequential dip in Q3 EBITDA.

Specialty Services Expansion and Future Potential

Specialty services, including neuropsych testing, TMS, and Spravato for treatment-resistant depression, are a key growth driver, expected to grow approximately 40% this year. The company is expanding these services into additional centers and is monitoring the potential for psychedelics, viewing them as a significant future opportunity to improve patient outcomes and contribute to growth and margins.

EHR Transition and Technology Enablement

LifeStance is preparing for a transition to a new EHR vendor in 2027, which is expected to be a critical enabler for streamlining operations, enhancing patient and clinician experience, and improving clinical outcomes. The company is also deploying digital, AI-enabled, and workflow automation tools to drive efficiency and improve patient access across various functions.

Geographic Expansion via Disciplined M&A

The company sees significant opportunity to increase density in existing markets and expand into new geographies, currently present in only about half of the 150 largest U.S. markets. Small tuck-in acquisitions are the preferred approach for entering new geographies, as demonstrated by a recent acquisition in Arizona, with a growing pipeline of strategic opportunities.

Focus on Clinical Outcomes and Payer Relationships

LifeStance continues to emphasize clinical excellence, with recent data showing that at least 75% of patients experienced clinically meaningful improvement in anxiety and depression symptoms across diverse populations. This focus on measurable outcomes is seen as a key differentiator, strengthening partnerships with payers who are increasingly shifting from solely access-based to outcomes-based considerations.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.